SCHEMBL9242962

SCHEMBL9242962

CCOC(=O)N1CCN(CCCl)CC1

nearest known ligand 0.62

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.62
HTT P42858 3/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
POLB P06746 1/20 0.62
KMT2A Q03164 3/20 0.54
TSHR P16473 2/20 0.54
MAPT P10636 2/20 0.54
LMNA P02545 2/20 0.54
HPGD P15428 1/20 0.54
HRH2 P25021 4/20 0.50
HRH1 P35367 4/20 0.50
RECQL P46063 1/20 0.50
KDM4E B2RXH2 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11337882 1.00 ALDH1A1 (0.62) ALDH1A1HTTSMN1; SMN2POLBKMT2A
Hydrochloric Acid SCHEMBL10760926 0.98 ALDH1A1 (0.61) ALDH1A1HTTSMN1; SMN2POLBKMT2A
SCHEMBL3270714 0.89 ALDH1A1 (0.59) ALDH1A1HTTSMN1; SMN2POLBKMT2A
SCHEMBL46979 0.85 SMN1; SMN2 (0.56) ALDH1A1HTTSMN1; SMN2POLBMAPT
SCHEMBL9051052 0.85 ALDH1A1 (0.56) ALDH1A1HTTSMN1; SMN2POLBKMT2A
SCHEMBL6316085 0.83 CYP2D6 (0.42) ALDH1A1HTTSMN1; SMN2POLBKMT2A
SCHEMBL13845058 0.83 ALDH1A1 (0.55) ALDH1A1HTTSMN1; SMN2POLBKMT2A
Hydrochloric Acid SCHEMBL27445572 0.83 ALDH1A1 (0.58) ALDH1A1HTTSMN1; SMN2POLBKMT2A
SCHEMBL18482713 0.83 HRH2 (0.47) ALDH1A1HTTSMN1; SMN2POLBKMT2A
SCHEMBL10985089 0.82 ALDH1A1 (0.72) ALDH1A1HTTSMN1; SMN2POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220267305-A1 MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2022-08-25 US disclosed
CN-1033453-C Pyridylthiazolidine carboxylic acid amide derivative and its preparing method SANKYO CO (JP) 1996-12-04 CN disclosed
CN-1130630-A Pyridylthiazolidinecarboxylic acid amide derivatives, their preparation and their therapeutic uses SANKYO CO (JP) 1996-09-11 CN disclosed
EP-0686635-A1 Pyridylthiazolidinecarboxylic acid amide derivatives, their preparation and their therapeutic uses Sankyo Company Limited (JP) 1995-12-13 EP disclosed
US-5470851-A Antihistamine, anticoagulants SANKYO COMPANY, LIMITED (JP) 1995-11-28 US disclosed
EP-0549364-A1 Pyridylthiazolidinecarboxylic acid amide derivatives, their preparation and their therapeutic uses Sankyo Company Limited (JP) 1993-06-30 EP disclosed
US-4243805-A 3 Fluoro-10-piperazino-8-substituted 10,11-dihydrodibenzo-(bf) thiepins and method for the preparation thereof SPOFA, SPOJENE PODNIKY PRO ZDRAVOTNICKOU VYROBU (CS) 1981-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220267305-A1 MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE ADRM1, MDM2, ESR2 ALDH1A1 2935/4885HTT 607/4885SMN1; SMN2 1543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.